Physician profile
Stephanie A Yoder
NPI 1669442158
$1,381.72
in general payments reported to CMS, 2019-2025
20 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.69 · 2022: $294 · 2023: $312 · 2024: $430 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $212.60 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $200.01 | 2022-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $167.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $130.34 | 2021-2024 | Bexsero, Pediarix, Menveo |
| Neos Therapeutics, LP | $114.29 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sanofi-Aventis U.S. LLC | $95.72 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $76.07 | 2021-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $63.39 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Kaleo, INC. | $54.77 | 2023-2024 | Auvi-Q |
| Cranial Technologies, INC | $37.98 | 2023-2024 | Doc Band |
| Pfizer INC. | $32.52 | 2022-2024 | |
| Mindray Ds USA, INC. | $30.09 | 2022-2023 | Patient Monitor, Na Electrode,Indirect,International |
| Biomerieux INC | $28.87 | 2025 | |
| Tris Pharma INC | $28.57 | 2022-2023 | Dyanavel Xr |
| Biomarin Pharmaceutical INC. | $22.22 | 2025 | Voxzogo 1.2mg |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $20.82 | 2025 | Zelsuvmi |
| Takeda Pharmaceuticals U.S.A., INC. | $19.33 | 2025 | Elaprase |
| Sobi, INC | $17.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.28 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.